Rich Horgan (L) with his late brother, Terry (Cure Rare Disease via YouTube)
N-of-1 CRISPR trial ends with a death as nonprofit digs into what happened
Almost two months after the nonprofit Cure Rare Disease received FDA clearance to administer its first-in-human CRISPR therapeutic for Duchenne muscular dystrophy, the nonprofit announced …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
